1. Home
  2. |Insights
  3. | First 100 Days: Navigating New Frontiers: Life Sciences in the Trump Era

First 100 Days: Navigating New Frontiers: Life Sciences in the Trump Era

Webinar | 02.25.25, 1:00 PM EST - 2:30 PM EST

Please join us for a post-Election webinar with the heads of our Government Affairs group who will address the myriad of areas in the Life Sciences industry that will likely be impacted by the new administration, including FDA, NIH, drug pricing, imports, and exports.

Our resident Government Affairs experts Aaron Cummings, former Chief of Staff to U.S. Senator Chuck Grassley (R-IA), Stephen Holland, former Senior Health Counsel to the House Committee on Energy & Commerce and Ranking Member Frank Pallone, Jr. (D-NJ), and Jim Flood, former counsel to Senator Charles E. Schumer (D-NY), will respond to rapid-fire questions posed by lawyers from Crowell’s Health Care, Intellectual Property, International Trade, Government Contracts, and Corporate Transactions practice groups. Through this industry-focused discussion, our team will help you begin to identify, understand, and navigate the impact of the new administration on your business.

For more information, please visit these areas: Health Care

Participants

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

View All Insights